Catheter Precision Files 8-K/A Amendment

TL;DR

Catheter Precision filed an 8-K/A amendment on Oct 25th covering material agreements and equity sales.

AI Summary

Catheter Precision, Inc. filed an 8-K/A on November 4, 2024, to amend a previous filing. The amendment pertains to an entry into a material definitive agreement, unregistered sales of equity securities, and material modifications to the rights of security holders, with the earliest event reported on October 25, 2024.

Why It Matters

This amendment provides updated information regarding significant corporate actions, including agreements and equity sales, which could impact investors' understanding of the company's financial and operational status.

Risk Assessment

Risk Level: medium — Amendments to 8-K filings often indicate significant corporate events that could impact stock price and investor confidence.

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• October 25, 2024 (date) — Earliest event reported
• November 4, 2024 (date) — Filing date
• Ra Medical Systems, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share VTAK NYSE American Indic
• $1.00 — s, priced at a public offering price of $1.00 per unit, with each unit consisting of
• $0.9999 — s, priced at a public offering price of $0.9999 per unit, with each unit consisting of
• $30.00 — hey each have a fixed exercise price of $30.00 per common share. Also as previously r
• $40.00 — ries E Warrant has an exercise price of $40.00 and a term of five years from date of t
• $0.70 — ries I Warrants from $1.00 per share to $0.70 per share, and also reduced the exercis
• $3.7 million — gregate gross proceeds of approximately $3.7 million from the exercise of the Existing Warra
• $1,185,000 — on received an additional approximately $1,185,000 upon the exercise of 1,010,000 Series H
• $299,486 — adenburg") the following compensation: $299,486.94, which was equal to 8.0% of the aggr
• $37,435 — Series E, F, G, H, and/or I Warrants, $37,435.87, as a management fee equal to 1% of
• $40,000 — nt raised from the warrant exercises, $40,000, in reimbursement of expenses, and Wa

Filing Documents

• catheter_8ka.htm (8-K/A) — 47KB
• catheter_ex42.htm (EX-4.2) — 99KB
• catheter_ex102.htm (EX-10.2) — 63KB
• catheter_ex102img3.jpg (GRAPHIC) — 6KB
• 0001654954-24-013701.txt ( ) — 381KB
• catheter-20241025.xsd (EX-101.SCH) — 6KB
• catheter-20241025_lab.xml (EX-101.LAB) — 14KB
• catheter-20241025_cal.xml (EX-101.CAL) — 1KB
• catheter-20241025_pre.xml (EX-101.PRE) — 9KB
• catheter-20241025_def.xml (EX-101.DEF) — 2KB
• catheter_8ka_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Warrant Repricing As previously reported, on August 30, 2024, Catheter Precision, Inc., a Delaware corporation (the "Company"), entered into an Underwriting Agreement (the "Underwriting Agreement") with Ladenburg Thalmann & Co. Inc., as representative of the underwriters named in the Underwriting Agreement (the "Underwriters"), pursuant to which the Company issued and sold, in a firm commitment underwritten public offering by the Company (the "Public Offering"), (i) 805,900 common stock units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the six month anniversary of the date of issuance (a "Series H Warrant"), one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the eighteen month anniversary of the date of issuance (a "Series I Warrant"), and one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the five year anniversary of the date of issuance (a "Series J Warrant"), and (ii) 2,773,000 pre-funded units, priced at a public offering price of $0.9999 per unit, with each unit consisting of one pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001 per share that has no expiration date (a "Pre-Funded Warrant" and together with the Series H Warrants, Series I Warrants and Series J Warrants, the "Warrants"), one Series H Warrant, one Series I Warrant and one Series J Warrant. The Public Offering closed on September 3, 2024. Also, as previously reported, on January 9, 2023, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Armistice Master Fund Ltd. ("Armistice"). Pursuant to the Securities Purchase Agreement, Armistice agreed to purchase (a) Class A Units, each

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information disclosed in Item 1.01 of this Current Report on Form 8-K regarding the unregistered sale of New Warrants, along with the New Warrant Shares issuable upon the exercise thereof, and the exercise of the modified Series F Warrants and the issuance of the shares of common stock in connection therewith, and the Placement Agent Warrants, along with the shares of common stock issuable upon the exercise thereof, is incorporated herein by reference. The New Warrants described in Item 1.01 above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the New Warrant Shares issuable upon the exercise thereof, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Placement Agent Warrants described in Item 1.01 above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the share of common stock issuable upon the exercise thereof, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

03. Material Modifications to Rights of Security Holders

Item 3.03. Material Modifications to Rights of Security Holders. The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Description Form File No. Exhibit Filing Date 4.1 Form of Series K Warrant. 8-K 001-38677 4.1 10/25/2024 4.2 Form of Placement Agent Warrant 10.1 Form of Warrant Inducement Offer Letter. 8-K 001-38677 10.1 10/25/2024 10.2 Investment Banking Agreement dated May 9, 2024 99.1 Press Release dated October 25, 2024. 8-K 001-38677 99.1 10/25/2024 104 Cover Page Interactive Data File (formatted as inline XBRL). 4

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: November 4, 2024 By: /s/ Margrit Thomassen Margrit Thomassen Interim Chief Financial Officer 5

View Full Filing

View this 8-K/A filing on SEC EDGAR